Son B. Le
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Son B. Le has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- David D. Tran
University of Southern California 3 Division of Neuro-Oncology, Keck School of Medicine, Norris Comprehensive Cancer Center Los Angeles, California
123 shared publications - Dongjiang Chen
Division of Neuro-Oncology, Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
122 shared publications - Tianyi Liu
Division of Neuro-Oncology, Brain Tumor Center, Keck School of Medicine of University of Southern California, Los Angeles, California
122 shared publications - Alberto Riva
Interdisciplinary Center of Biotechnology Research, University of Florida, Gainesville, USA
82 shared publications - Dan Jin
University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA
82 shared publications - Mathew Sebastian
University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA
82 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S11 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Bulk RNA-seq characteristics of the 3 LN GBM cell lines and human monocyte-derived DC for the human GBM ➝ iDC-APC conversion (Supporting Main Figure 7)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S11 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Bulk RNA-seq characteristics of the 3 LN GBM cell lines and human monocyte-derived DC for the human GBM ➝ iDC-APC conversion (Supporting Main Figure 7)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S8 from The EP3–ZNF488 Axis Promotes Self-Renewal of Glioma Stem-Like Cells to Induce Resistance to Tumor Treating Fields
EP3 promotes self-renewal in TTFields-resistant GBM cells. (Supporting Main Figure 4)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S8 from The EP3–ZNF488 Axis Promotes Self-Renewal of Glioma Stem-Like Cells to Induce Resistance to Tumor Treating Fields
EP3 promotes self-renewal in TTFields-resistant GBM cells. (Supporting Main Figure 4)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S17 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
CFDs for human LN GBM → iDC-APC conversion (Support Main Figure 7)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S17 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
CFDs for human LN GBM → iDC-APC conversion (Support Main Figure 7)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S9 from The EP3–ZNF488 Axis Promotes Self-Renewal of Glioma Stem-Like Cells to Induce Resistance to Tumor Treating Fields
EP3i re-sensitizes freshly isolated TTFields-resistant GSC to the cytotoxic effects of TTFields as measured by the extreme limiting dilution assay. (Supporting Main Figure 5)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S9 from The EP3–ZNF488 Axis Promotes Self-Renewal of Glioma Stem-Like Cells to Induce Resistance to Tumor Treating Fields
EP3i re-sensitizes freshly isolated TTFields-resistant GSC to the cytotoxic effects of TTFields as measured by the extreme limiting dilution assay. (Supporting Main Figure 5)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S21 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Human PU.1/IKZF1 (hPI) is 50%-100% more efficient at inducing CD45+ and CD45+MHCII+ cells compared to hP-hF3 and hPIB in U87 GBM cells. (Supporting Main Figure 7)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S21 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Human PU.1/IKZF1 (hPI) is 50%-100% more efficient at inducing CD45+ and CD45+MHCII+ cells compared to hP-hF3 and hPIB in U87 GBM cells. (Supporting Main Figure 7)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S15 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
ScRNA-seq analysis of fresh GBM tumors reveals the absence of a significant population of tumor-derived APCs with DC-like markers. (Supporting Main Figures 7)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S15 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
ScRNA-seq analysis of fresh GBM tumors reveals the absence of a significant population of tumor-derived APCs with DC-like markers. (Supporting Main Figures 7)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S12 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
All public murine datasets curated for ML predictions (supporting Main Figure 1)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S12 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
All public murine datasets curated for ML predictions (supporting Main Figure 1)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S14 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Top 20 CFDs for conversion of murine GBM to myeloid cells (supporting Main Figure 1)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S14 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Top 20 CFDs for conversion of murine GBM to myeloid cells (supporting Main Figure 1)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Conversion of murine GBM cells to iDC-APCs (Supporting Main Figure 1)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy
Conversion of murine GBM cells to iDC-APCs (Supporting Main Figure 1)